Korro Bio, Inc. KRRO
14.75 USD +0.02 (+0.14%)
At closeNov 6, 2026, 4:26 PM EST
14.75 0.00 0.00%
After hours · Nov 6, 4:26 PM ET
14.69 Day range 15.74
5.28 52-week range 33.84
- YTD
- +84.14%
- 1 year
- -54.71%
News
benzinga.com Korro Bio Q3 EPS $(0.98) Beats $(1.26) Estimate Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.26) by 22.22 percent. This is a 48.96 percent increase over losses of $(1.92)…
globenewswire.com Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market…
benzinga.com Korro Bio Announces Preclinical Results Showing KRRO-111 Potential To Treat Both Lung And Liver Manifestations Of Alpha-1 Antitrypsin Deficiency Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-foldKRRO-111 reduced pathogenic hepatic Z-AAT by up…
benzinga.com HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $15 price target.
benzinga.com Korro Bio Doses First First Group Of Patients In Its Phase 1/2 Clinical Study Of KRRO-121 To Treat Hyperammonemia In Patients With Urea Cycle Disorders Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers IM Cannabis (NASDAQ:IMCC) stock increased by 246.0% to $6.02 during Friday's regular session. The market value of their outstanding shares is at $1.0 million. SkyAI (NASDAQ:SKYA) stock rose…- benzinga.com HC Wainwright & Co. Reiterates Buy on Korro Bio, Maintains $15 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Korro Bio (NASDAQ:KRRO) with a Buy and maintains $15 price target.
benzinga.com Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.31) by 18.32 percent. This is a 60.95 percent increase over losses of $(2.74)…- benzinga.com Korro Bio Announces Addition Of KRRO-111 For Potential Treatment Of AATD To Pipeline Of Therapeutic Programs In Development Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungsDemonstrated >90% editing of…
- benzinga.com HC Wainwright & Co. Maintains Buy on Korro Bio, Lowers Price Target to $15 HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Korro Bio (NASDAQ:KRRO) with a Buy and lowers the price target from $20 to $15.
benzinga.com Citigroup Initiates Coverage On Korro Bio with Buy Rating, Announces Price Target of $21 Citigroup analyst Yigal Nochomovitz initiates coverage on Korro Bio (NASDAQ:KRRO) with a Buy rating and announces Price Target of $21.
benzinga.com Korro Bio Q1 EPS $(1.69) Beats $(2.17) Estimate Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.69) per share which beat the analyst consensus estimate of $(2.17) by 22.12 percent. This is a 32.13 percent increase over losses of $(2.49)…- benzinga.com Korro Bio Presents Oral, Poster Presentations Of Data From Its Oligonucleotide Delivery Based RNA Editing Technology Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced oral and…
benzinga.com Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and long-term growth plans.- benzinga.com Cantor Fitzgerald Maintains Overweight on Korro Bio, Raises Price Target to $22 Cantor Fitzgerald analyst Steve Seedhouse maintains Korro Bio (NASDAQ:KRRO) with a Overweight and raises the price target from $21 to $22.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session 
benzinga.com Raymond James Upgrades Korro Bio to Outperform, Announces $23 Price Target Raymond James analyst Steven Seedhouse upgrades Korro Bio (NASDAQ:KRRO) from Market Perform to Outperform and announces $23 price target.
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session 
benzinga.com Korro Bio Q4 EPS $(5.32) Misses $(2.05) Estimate, Sales $1.290M Beat $670.000K Estimate Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(5.32) per share which missed the analyst consensus estimate of $(2.05) by 159.39 percent. This is a 135.4 percent decrease over losses of…- benzinga.com Korro Bio Secures ~$85M PIPE Financing Via Subscription Agreement Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA…
benzinga.com eBay To Rally More Than 48%? Here Are 10 Top Analyst Forecasts For Thursday 
benzinga.com This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Meta Platforms To Rally More Than 71%? Here Are 10 Top Analyst Forecasts For Thursday - benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Why Cisco Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket 
benzinga.com This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com Uber To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Thursday 
benzinga.com This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday